LENZ Therapeutics, Inc.

NASDAQ:LENZ

Biotechnology

Healthcare
$3.34 -6.62%

-$0.42 today

Market cap
$104.94M
Beta
1.47
P/E (TTM)
-1.7
EPS (TTM)
-$3.48
52W Low $5.85High $50.40

Volume 0.64M

Average 0.89M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$69.17M

FY 2025 · Annual

Investing Cash Flow

-$75.67M

FY 2025 · Annual

Financing Cash Flow

$149.75M

FY 2025 · Annual

-24.8% YoY

Cash Flow Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Net Income(70.76M)(101.05M)(69.97M)(49.77M)(82.13M)
Depreciation & Amortization734K8.35M15K58K(3.12M)
Deferred Income Tax00000
Stock-Based Compensation001.34M6.37M12.55M
Change in Working Capital(2.5M)(7.21M)9.41M(13.09M)3.25M
Accounts Receivables0000(329K)
Inventory0000(4.28M)
Accounts Payables1.83M194K856K(4.28M)(90K)
Other Working Capital(4.32M)(7.4M)8.55M(8.81M)7.95M
Other Non-Cash Items19.67M11.93M(1.18M)(2.95M)279K
Operating Cash Flow(52.85M)(87.98M)(60.38M)(59.39M)(69.17M)
Capital Expenditures(5.74M)(6.59M)(30K)(468K)(827K)
Acquisitions (Net)00000
Purchases of Investments0(405.52M)(52.09M)(241.91M)(280.8M)
Sales of Investments0170.25M22.5M87.9M205.96M
Other Investing Activities00000
Investing Cash Flow(5.74M)(241.86M)(29.62M)(154.48M)(75.67M)
Debt Repayment00000
Common Stock Issued417.16M676K203K79.51M149.75M
Common Stock Repurchased0(79K)000
Dividends Paid00000
Other Financing Activities306K0(2.48M)119.49M0
Financing Cash Flow417.47M597K80.7M199M149.75M
Effect of Forex Changes(1.72M)0000
Net Change in Cash357.16M(329.25M)(9.3M)(14.87M)4.91M
Free Cash Flow(58.59M)(94.57M)(60.41M)(59.86M)(70M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$82.1M
+ D&A-$3.1M
+ Stock-Based Comp$12.5M
+ Deferred Tax$0
+ Working Capital$3.3M
+ Other Non-Cash$279.0K
= Operating Cash Flow-$69.2M
- Capex-$827.0K
= Free Cash Flow-$70.0M

Analysis

FY2025 free cash flow is -$70.0M. FCF conversion is 85.2% of net income. Operating cash flow was -$69.2M, with capex of -$827.0K. The largest bridge item is Stock-Based Comp at $12.5M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 5, 2026
SC 13GSC 13G filingNov 4, 2026
4Statement of changes in beneficial ownershipNov 3, 2026
10-QQuarterly reportNov 3, 2026
4Statement of changes in beneficial ownershipNov 2, 2026

Does LENZ generate free cash flow?

LENZ Therapeutics, Inc. (LENZ) generated -$70.00M of free cash flow in fiscal 2025.

How much operating cash flow does LENZ produce?

Operating cash flow was -$69.17M, before capital expenditures of $827,000.00.